Thermo Fisher Announces Expansion Of St. Louis Biologics Site

Thermo Fisher is investing $50 million in its St. Louis, Missouri site, which is one of the company’s Centers of Excellence (COE) for Biological Commercial Manufacturing. The investment is part of a deliberate strategy to continue expansion of the company’s global network of biologic drug substance capabilities for clinical and commercial supply.

The project includes expansion to the existing manufacturing building #2 by 64,000 square feet, which will double its manufacturing capacity and will be operational in 2019.  The expansion will take advantage of the Thermo Fisher bioproduction “eco-system” for bioreactors, consumables, and factory automation.  With this capacity expansion, Thermo Fisher will have the second largest base of single-use bioproduction capacity at a CDMO in the world. The investment will also allow for further expansion in the future. Approximately 80 new technical jobs are expected to be added.

The Patheon Biologics Network of four sites around the globe is growing at a rapid pace and has standardized on the 2000L, single-use platform as the preferred option in new drug development through to commercialization. The St. Louis site currently provides process development, clinical cGMP manufacturing, Phase III process performance validation, and commercial manufacturing using both fed batch and perfusion processes. The St. Louis COE, with more than a decade of manufacturing experience, has in-house analytical capabilities for Quality Assurance and Quality Control.

Thermo Fisher's Pharma Services develops unique solutions and business models to help customers manage the clinical development process and provides flexible manufacturing options to address client needs in an evolving marketplace.  The biologics network is complemented by a global network of sites to formulate and manufacture sterile injectable drug product for clinical trials and commercial supply.